Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JNJ NASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$191.79+0.3%$180.09$140.68▼$194.40$460.40B0.49.56 million shs10.61 million shsNVAXNovavax$8.48-4.8%$8.44$5.01▼$11.55$1.45B2.744.49 million shs5.19 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson+0.43%+0.43%+8.68%+17.20%+16.75%NVAXNovavax-4.83%-1.28%-0.93%+21.14%-16.45%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$191.79+0.3%$180.09$140.68▼$194.40$460.40B0.49.56 million shs10.61 million shsNVAXNovavax$8.48-4.8%$8.44$5.01▼$11.55$1.45B2.744.49 million shs5.19 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson+0.43%+0.43%+8.68%+17.20%+16.75%NVAXNovavax-4.83%-1.28%-0.93%+21.14%-16.45%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJNJJohnson & Johnson 2.73Moderate Buy$199.594.07% UpsideNVAXNovavax 1.88Reduce$9.8015.57% UpsideCurrent Analyst Ratings BreakdownLatest NVAX and JNJ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/15/2025JNJJohnson & JohnsonArgusSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$210.0010/15/2025JNJJohnson & JohnsonRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$174.00 ➝ $209.0010/15/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$190.0010/15/2025JNJJohnson & JohnsonStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$165.00 ➝ $190.0010/15/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$213.00 ➝ $215.0010/15/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$198.00 ➝ $204.0010/14/2025JNJJohnson & JohnsonCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/14/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$190.00 ➝ $214.0010/10/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$209.0010/10/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$176.00 ➝ $178.0010/8/2025NVAXNovavaxWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)(Data available from 10/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJNJJohnson & Johnson$88.82B5.20$13.16 per share14.57$29.69 per share6.46NVAXNovavax$682.16M2.02N/AN/A($3.89) per share-2.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJNJJohnson & Johnson$14.07B$9.3518.5117.332.4027.26%33.08%13.30%N/ANVAXNovavax-$187.50M$2.283.72106.000.1239.20%-142.33%28.65%11/11/2025 (Estimated)Latest NVAX and JNJ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025NVAXNovavax-$0.44N/AN/AN/A$55.63 millionN/A10/14/2025Q3 2025JNJJohnson & Johnson$2.76$2.80+$0.04$2.12$23.73 billion$23.99 billion8/6/2025Q2 2025NVAXNovavax-$0.07$0.62+$0.69$0.62$149.19 million$239.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJNJJohnson & Johnson$5.202.71%N/A55.61%64 YearsNVAXNovavaxN/AN/AN/AN/AN/ALatest NVAX and JNJ DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date10/14/2025JNJJohnson & Johnsonquarterly$1.302.72%11/25/202511/25/202512/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJNJJohnson & Johnson0.501.010.76NVAXNovavax5.932.362.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJNJJohnson & Johnson69.55%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipJNJJohnson & Johnson0.16%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableNVAXNovavax1,990162.42 million160.80 millionOptionableNVAX and JNJ HeadlinesRecent News About These CompaniesNovavax (NVAX) Suffers a Larger Drop Than the General Market: Key InsightsOctober 16 at 6:46 PM | zacks.comNovavax, Inc. $NVAX Shares Acquired by Bayforest Capital LtdOctober 15 at 5:29 AM | marketbeat.comShah Capital pushes for Novavax’s sale on underperformance, Reuters saysOctober 14 at 5:37 PM | msn.comNovavax stock rises after major shareholder urges company saleOctober 14 at 5:37 PM | za.investing.comNovavax Major Shareholder Calls For Sale Of Company To Larger Pharma EntityOctober 14 at 5:37 PM | msn.comHedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion PotentialOctober 14 at 1:31 PM | benzinga.comAnalysts Think These Stocks Could More Than Double in Value (NVAX)...October 14 at 11:54 AM | marketbeat.comShah Capital pushes for Novavax's sale on persistent underperformance, marketing misstepsOctober 14 at 6:09 AM | reuters.comNovavax (NASDAQ:NVAX) Receives Sell (D+) Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comInvestors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowOctober 8, 2025 | zacks.comNovavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone PaymentOctober 7, 2025 | prnewswire.comShah Capital Management Has $72.52 Million Stock Position in Novavax, Inc. $NVAXOctober 7, 2025 | marketbeat.comNovavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You TradeOctober 6, 2025 | zacks.comCDC adopts individual-based decision-making for COVID-19 shotsOctober 6, 2025 | msn.comNovavax (NVAX) Is Up 10.6% After Sanofi Expands Matrix-M Licensing Agreement - Has the Bull Case Changed?October 4, 2025 | finance.yahoo.comA Fresh Look at Novavax (NVAX) Valuation After Recent Share Price ReboundOctober 3, 2025 | finance.yahoo.comInvestors Purchase Large Volume of Call Options on Novavax (NASDAQ:NVAX)October 2, 2025 | marketbeat.comNovavax (NASDAQ:NVAX) Trading 6.4% Higher - What's Next?October 1, 2025 | marketbeat.comNovavax (NVAX) Exceeds Market Returns: Some Facts to ConsiderSeptember 30, 2025 | zacks.comNovavax Amends Deal With Sanofi, Broadens PartnershipSeptember 30, 2025 | msn.comNovavax Announces Progress on Sanofi AgreementSeptember 30, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Why AbbVie and Johnson & Johnson Could Outperform PfizerBy Chris Markoch | October 8, 2025Johnson & Johnson Stock Can Keep Rising as Strategy Pays OffBy Thomas Hughes | October 15, 2025NVAX and JNJ Company DescriptionsJohnson & Johnson NYSE:JNJ$191.79 +0.62 (+0.32%) Closing price 10/16/2025 03:59 PM EasternExtended Trading$191.98 +0.19 (+0.10%) As of 10/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novavax NASDAQ:NVAX$8.48 -0.43 (-4.83%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$8.66 +0.18 (+2.12%) As of 10/16/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Buys Rival's Patent Treasure Trove in Strategic Move Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
